A New Device for Managing Refractory Epistaxis in ICU Patients with COVID-19

A New Device for Managing Refractory Epistaxis in ICU Patients with COVID-19

Author Info

Corresponding Author
Olivier Choussy
Surgical Oncological Department, Head and Neck, Institut Curie, PSL Research University, Paris, France


Epistaxis is a common and a well-known symptom. Nasal packing is an effective treatment in most cases [1]. The COVID-19 disease treatment includes conventional or high flow nasal oxygen therapy and systemic anticoagulation [2]. Patients in intensive care unit may require therapeutic anticoagulation for venous thromboembolism, hyperinflammatory status, extracorporeal membrane oxygenation (ECMO) and multiple other pathologies. The use of therapeutic anticoagulation increases risk of nose bleeding, and its management may be challenging. CAVI-T (Figures 1 & 2) is a new asymmetrical low-pressure balloon that have shown promising results to control epistaxis in emergency. We report herein the management of severe epistaxis in two COVID-19 patients admitted to ICU for severe respiratory failure.

Article Info

Article Type
Case Report
Publication history
Received: Tue 22, Jun 2021
Accepted: Sat 18, Sep 2021
Published: Thu 30, Sep 2021
© 2023 Olivier Choussy. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.SCR.2021.09.13